Page last updated: 2024-10-30

letrozole and Cancer of Pelvis

letrozole has been researched along with Cancer of Pelvis in 3 studies

Research Excerpts

ExcerptRelevanceReference
"Letrozole was then given at a daily dose of 2."5.31Endometrial stromal sarcoma: objective response to letrozole. ( Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J, 2001)
" The long-term use of aromatase inhibitor therapy is thought to be effective and safe for patients with recurrence after BSO."1.46Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata. ( Ando, H; Kusunoki, S; Matsuoka, S; Ogishima, D; Ota, T; Sugimori, Y, 2017)
"Letrozole was then given at a daily dose of 2."1.31Endometrial stromal sarcoma: objective response to letrozole. ( Aghajanian, C; Maluf, FC; Sabbatini, P; Schwartz, L; Xia, J, 2001)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ando, H1
Kusunoki, S1
Ota, T1
Sugimori, Y1
Matsuoka, S1
Ogishima, D1
Pink, D1
Lindner, T1
Mrozek, A1
Kretzschmar, A1
Thuss-Patience, PC1
Dörken, B1
Reichardt, P1
Maluf, FC1
Sabbatini, P1
Schwartz, L1
Xia, J1
Aghajanian, C1

Other Studies

3 other studies available for letrozole and Cancer of Pelvis

ArticleYear
Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata.
    The journal of obstetrics and gynaecology research, 2017, Volume: 43, Issue:9

    Topics: Adult; Aromatase Inhibitors; Female; Humans; Leiomyomatosis; Letrozole; Neoplasm Recurrence, Local;

2017
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
    Gynecologic oncology, 2006, Volume: 101, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Endometrial Stromal Tumors; Estrogen Replacement Thera

2006
Endometrial stromal sarcoma: objective response to letrozole.
    Gynecologic oncology, 2001, Volume: 82, Issue:2

    Topics: Abdominal Neoplasms; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Letrozole; Liver

2001